Literature DB >> 7593456

The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess.

V R Obeyesekere1, P Ferrari, R K Andrews, R C Wilson, M I New, J W Funder, Z S Krozowski.   

Abstract

The 11 beta-hydroxysteroid dehydrogenase type II enzyme (11 beta HSD2) inactivates glucocorticoids in the kidney and thus permits aldosterone to occupy the non-selective mineralocorticoid receptor in epithelial tissues. We have recently described a C to T transition in the HSD11B2 gene which results in an arginine to cysteine mutation (R337C) in the 11 beta HSD2 enzyme in a consanguineous family with three siblings suffering from Apparent Mineralocorticoid Excess (AME). In the present study we have examined the metabolism of cortisol in mammalian cells transfected with plasmids expressing the wild type and mutant enzymes. In whole cells the Km of the normal enzyme was 110nM, while the enzyme containing the R337C mutation displayed a Km of 1010nM. Further experiments revealed that the mutant was totally inactive in cell free preparations, suggesting that it has additional properties which may compromise its activity in whole cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593456     DOI: 10.1210/jcem.80.11.7593456

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence.

Authors:  Jonathan R Manning; Matthew A Bailey; Dinesh C Soares; Donald R Dunbar; John J Mullins
Journal:  Physiol Genomics       Date:  2010-06-22       Impact factor: 3.107

2.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  M I New; R C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.

Authors:  Mabel Yau; Shozeb Haider; Ahmed Khattab; Chen Ling; Mehr Mathew; Samir Zaidi; Madison Bloch; Monica Patel; Sinead Ewert; Wafa Abdullah; Aysenur Toygar; Vitalii Mudryi; Maryam Al Badi; Mouch Alzubdi; Robert C Wilson; Hanan Said Al Azkawi; Hatice Nur Ozdemir; Wahid Abu-Amer; Jozef Hertecant; Maryam Razzaghy-Azar; John W Funder; Aisha Al Senani; Li Sun; Se-Min Kim; Tony Yuen; Mone Zaidi; Maria I New
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

Review 4.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

5.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 6.  11β-hydroxysteroid dehydrogenases: A growing multi-tasking family.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

7.  Case Report: Application of whole exome sequencing for accurate diagnosis of rare syndromes of mineralocorticoid excess.

Authors:  Ranjit Narayanan; Shamsudheen Karuthedath Vellarikkal; Rijith Jayarajan; Ankit Verma; Vishal Dixit; Vinod Scaria; Sridhar Sivasubbu
Journal:  F1000Res       Date:  2016-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.